New cancer drug RS-0139 tested in humans for first time

NCT ID NCT04261413

Completed Disease control Sponsor: RS Arastirma Egitim Danismanlik Ilac Sanayi Ticaret A.S. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tested a new drug called RS-0139 in 16 people with advanced solid tumors that had stopped responding to standard treatments. The drug is designed to target tumors specifically, and the main goals were to find a safe dose and understand how the body processes it. Researchers also looked for signs of tumor shrinkage and changes in tumor markers.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: RS-0139 (a tumor-targeted prodrug)
What this could lead to: If successful, this could lead to a new treatment option for advanced solid tumors that have not responded to standard therapies.
What could go wrong: This is a very early, small Phase 1 trial with only 16 participants, focused on safety and dosing. It is too soon to know if the drug will effectively shrink tumors or improve survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMORS

Contacts and locations

Locations

Abdurrahman Yurtaslan Ankara Onkoloji Eğitim ve Araştırma Hastanesi

Ankara, Turkey (Türkiye)
Koç University Hospital Phase I Center

Istanbul, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.